NextCure (NXTC) Competitors $0.47 -0.03 (-5.64%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NXTC vs. KPTI, PMVP, AVTX, CTOR, PRLD, QNCX, ICCC, ACRV, MRSN, and OTLKShould you be buying NextCure stock or one of its competitors? The main competitors of NextCure include Karyopharm Therapeutics (KPTI), PMV Pharmaceuticals (PMVP), Avalo Therapeutics (AVTX), Citius Oncology (CTOR), Prelude Therapeutics (PRLD), Quince Therapeutics (QNCX), ImmuCell (ICCC), Acrivon Therapeutics (ACRV), Mersana Therapeutics (MRSN), and Outlook Therapeutics (OTLK). These companies are all part of the "pharmaceutical products" industry. NextCure vs. Karyopharm Therapeutics PMV Pharmaceuticals Avalo Therapeutics Citius Oncology Prelude Therapeutics Quince Therapeutics ImmuCell Acrivon Therapeutics Mersana Therapeutics Outlook Therapeutics NextCure (NASDAQ:NXTC) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, community ranking, profitability, dividends and earnings. Which has stronger earnings & valuation, NXTC or KPTI? NextCure has higher earnings, but lower revenue than Karyopharm Therapeutics. Karyopharm Therapeutics is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNextCureN/AN/A-$62.72M-$1.98-0.24Karyopharm Therapeutics$145.24M0.40-$143.10M-$15.29-0.44 Is NXTC or KPTI more profitable? NextCure has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -52.62%. Karyopharm Therapeutics' return on equity of 0.00% beat NextCure's return on equity.Company Net Margins Return on Equity Return on Assets NextCureN/A -62.50% -53.67% Karyopharm Therapeutics -52.62%N/A -39.58% Do institutionals and insiders believe in NXTC or KPTI? 42.7% of NextCure shares are owned by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 13.3% of NextCure shares are owned by insiders. Comparatively, 2.8% of Karyopharm Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, NXTC or KPTI? NextCure has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Comparatively, Karyopharm Therapeutics has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Does the media prefer NXTC or KPTI? In the previous week, Karyopharm Therapeutics had 2 more articles in the media than NextCure. MarketBeat recorded 4 mentions for Karyopharm Therapeutics and 2 mentions for NextCure. NextCure's average media sentiment score of 1.43 beat Karyopharm Therapeutics' score of 0.16 indicating that NextCure is being referred to more favorably in the media. Company Overall Sentiment NextCure Positive Karyopharm Therapeutics Neutral Does the MarketBeat Community favor NXTC or KPTI? Karyopharm Therapeutics received 459 more outperform votes than NextCure when rated by MarketBeat users. Likewise, 72.42% of users gave Karyopharm Therapeutics an outperform vote while only 65.08% of users gave NextCure an outperform vote. CompanyUnderperformOutperformNextCureOutperform Votes8265.08% Underperform Votes4434.92% Karyopharm TherapeuticsOutperform Votes54172.42% Underperform Votes20627.58% Do analysts rate NXTC or KPTI? NextCure presently has a consensus price target of $3.50, suggesting a potential upside of 652.04%. Karyopharm Therapeutics has a consensus price target of $57.50, suggesting a potential upside of 751.85%. Given Karyopharm Therapeutics' higher possible upside, analysts clearly believe Karyopharm Therapeutics is more favorable than NextCure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NextCure 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Karyopharm Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryKaryopharm Therapeutics beats NextCure on 9 of the 16 factors compared between the two stocks. Get NextCure News Delivered to You Automatically Sign up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NXTC vs. The Competition Export to ExcelMetricNextCurePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.05M$6.90B$5.57B$7.82BDividend YieldN/A3.06%5.11%4.22%P/E Ratio-0.227.4522.4218.48Price / SalesN/A242.72394.10103.91Price / CashN/A65.8538.1834.62Price / Book0.116.516.774.25Net Income-$62.72M$143.21M$3.22B$248.23M7 Day Performance10.78%3.97%3.26%3.29%1 Month Performance-6.92%0.37%0.02%2.42%1 Year Performance-61.54%2.60%18.01%5.54% NextCure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NXTCNextCure4.646 of 5 stars$0.47-5.6%$3.50+652.0%-57.8%$13.05MN/A-0.2290Upcoming EarningsShort Interest ↓Positive NewsGap UpHigh Trading VolumeKPTIKaryopharm Therapeutics3.6315 of 5 stars$6.07+8.0%$57.50+847.3%-61.5%$52.02M$145.24M-5.95380Upcoming EarningsShort Interest ↑News CoveragePMVPPMV Pharmaceuticals2.2581 of 5 stars$1.00-3.8%$5.67+466.7%-43.5%$51.93MN/A-1.0050AVTXAvalo Therapeutics3.9027 of 5 stars$4.73-1.0%$33.00+597.7%-70.4%$50.48M$441,000.000.0040News CoverageCTORCitius OncologyN/A$0.70-4.0%$3.00+328.5%N/A$50.09MN/A0.00N/APositive NewsPRLDPrelude Therapeutics2.8824 of 5 stars$0.89-1.6%$4.00+351.2%-76.5%$50.05M$7M-0.50120Upcoming EarningsAnalyst ForecastNews CoverageGap DownQNCXQuince Therapeutics2.9807 of 5 stars$1.13-7.9%$8.00+606.1%+7.1%$49.99MN/A-0.9160News CoveragePositive NewsHigh Trading VolumeICCCImmuCell0.9561 of 5 stars$5.50+0.0%N/A+7.6%$49.42M$26.49M-11.0070Short Interest ↓Positive NewsACRVAcrivon Therapeutics3.3845 of 5 stars$1.55-5.5%$21.80+1,306.5%-85.6%$48.59MN/A-0.5758Insider TradeShort Interest ↓High Trading VolumeMRSNMersana Therapeutics3.871 of 5 stars$0.38+5.5%$4.00+942.2%-88.3%$47.83M$40.50M-0.63150Gap DownOTLKOutlook Therapeutics1.8399 of 5 stars$1.48-3.3%$10.20+589.2%-82.9%$47.39MN/A-0.2020Positive News Related Companies and Tools Related Companies KPTI Competitors PMVP Competitors AVTX Competitors CTOR Competitors PRLD Competitors QNCX Competitors ICCC Competitors ACRV Competitors MRSN Competitors OTLK Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NXTC) was last updated on 4/30/2025 by MarketBeat.com Staff From Our PartnersTop performing AI play of the decade…? (The answer will shock you)You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredChina’s next move could destroy U.S. techThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NextCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NextCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NXTC Stock Free NXTC Stock Alerts